The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
ConceptoMed AS is delighted to announce a new partner for the Norwegian hospital market. We have entered into a distribution agreement with Vingmed AS granting exclusive rights for marketing, sales and distribution of the LuerJack syringes in the hospital market in Norway.
On the 14th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack. ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following.
On the 31st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack. IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack - also on the 31st of August 2016.
ConceptoMed today hosted a very interesting and pleasant meeting with the Prime Minister of Norway, Erna Solberg We raised the question: With the healthcare worker's safety and patient safety in mind; do today's available disposable syringes and connectors fully enable healthcare providers to minimise occurrence of needlestick injuries and hospital acquired blood-borne infections?
The Board of Directors of ConceptoMed AS have the pleasure of announcing the successful completion of a private placement of equity in ConceptoMed AS. The share issue was oversubscribed and provided the company with 12 new shareholders. Gross proceeds from the private placement amounted to NOK 11,550,000 (€1.42 Million)
Email sent to __email__. Click the link there to follow ConceptoMed.
